The FDA has approved Invega (paliperidone extended-release tablets; Janssen) for the treatment of schizophrenia in adolescents 12–17 years of age. This approval was based on data from a six-week randomized, double-blind, placebo-controlled study using a fixed-dose weight-based treatment group design over a dose range of 1.5–12mg/day that demonstrated efficacy of Invega in adolescents.

Invega, an atypical antipsychotic, is already approved for use in adults for acute and maintenance treatment of schizophrenia, as well as acute treatment of schizoaffective disorder, as monotherapy or as an adjunct to mood stabilizer and/or antidepressants.

For more information call (800) 526-7736 or visit www.invega.com.